-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascendiant Capital Maintains Buy on Vivos Therapeutics, Raises Price Target to $3.1

Benzinga·06/04/2026 09:52:02
Listen to the news
Ascendiant Capital analyst Lucas Ward maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and raises the price target from $3 to $3.1.